APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR-T Therapy For B-Cell Malignancies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global CAR-T Therapy For B-Cell Malignancies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025197 pages

Choose your research edition.

Industry ResearchCAR-T Therapy For B-Cell Malignancies Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR-T Therapy For B-Cell Malignancies Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CAR-T Therapy For B-Cell Malignancies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR-T Therapy For B-Cell Malignancies Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR-T Therapy For B-Cell Malignancies Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global CAR-T Therapy For B-Cell Malignancies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for CAR-T Therapy For B-Cell Malignancies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of CAR-T Therapy For B-Cell Malignancies include IMCURE, JW Therapeutics, Johnson And Johnson, Novartis, Roche, CARsgen Therapeutics, Chongqing Precision Biotech, Gilead Sciences and HEBECELL, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global CAR-T Therapy For B-Cell Malignancies market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CAR-T Therapy For B-Cell Malignancies and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CAR-T Therapy For B-Cell Malignancies revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the CAR-T Therapy For B-Cell Malignancies market size, projected growth trends, production technologies, key applications, and end-use industries.

CAR-T Therapy For B-Cell Malignancies Segment by Company

IMCURE

JW Therapeutics

Johnson And Johnson

Novartis

Roche

CARsgen Therapeutics

Chongqing Precision Biotech

Gilead Sciences

HEBECELL

Fosun Kite Bio

Legend Biotech

Beihai Biotechnology

AstraZeneca

Regeneron Pharmaceuticals

Kite Pharma

Celgene

Bristol Myers Squibb

Bluebird Bio

CAR-T Therapy For B-Cell Malignancies Segment by Type

Universal CAR-T

Dual Targets CAR-T

Gene Modified Enhanced CAR-T

Multi Targets CAR-T

Single Target CAR-T

CAR-T Therapy For B-Cell Malignancies Segment by Application

Multiple Myeloma

B-Cell Acute Lymphoblastic Leukemia

B-Cell Non-Hodgkin's Lymphoma

Others

CAR-T Therapy For B-Cell Malignancies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR-T Therapy For B-Cell Malignancies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR-T Therapy For B-Cell Malignancies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR-T Therapy For B-Cell Malignancies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of CAR-T Therapy For B-Cell Malignancies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR-T Therapy For B-Cell Malignancies industry.

Chapter 3: Detailed analysis of CAR-T Therapy For B-Cell Malignancies companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR-T Therapy For B-Cell Malignanciesrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Universal CAR-T Table 3. Key Players of Dual Targets CAR-T Table 4. Key Players of Gene Modified Enhanced CAR-T Table 3. Key Players of Multi Targets CAR-T Table 4. Key Players of Single Target CAR-T Table 5. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Multiple Myeloma Table 7. Key Players of B-Cell Acute Lymphoblastic Leukemia Table 8. Key Players of B-Cell Non-Hodgkin's Lymphoma Table 9. Key Players of Others Table 10. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2021-2026) & (US$ Million) Table 12. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2021-2026) Table 13. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2027-2032) & (US$ Million) Table 14. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2027-2032) Table 15. CAR-T Therapy For B-Cell Malignancies Industry Trends Table 16. CAR-T Therapy For B-Cell Malignancies Industry Drivers Table 17. CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges Table 18. CAR-T Therapy For B-Cell Malignancies Industry Restraints Table 19. Global CAR-T Therapy For B-Cell Malignancies Revenue by Company (US$ Million) & (2021-2026) Table 20. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Company (2021-2026) Table 21. Global CAR-T Therapy For B-Cell Malignancies Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global CAR-T Therapy For B-Cell Malignancies Key Company Head Office and Area Served Table 23. Global CAR-T Therapy For B-Cell Malignancies Company, Product Type & Application Table 24. Global CAR-T Therapy For B-Cell Malignancies Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global CAR-T Therapy For B-Cell Malignancies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026) & (US$ Million) Table 29. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032) & (US$ Million) Table 30. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2021-2026) Table 31. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2027-2032) Table 32. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026) & (US$ Million) Table 34. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032) & (US$ Million) Table 35. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2021-2026) Table 36. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2027-2032) Table 37. IMCURE Company Information Table 38. IMCURE Business Overview Table 39. IMCURE CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 41. IMCURE Recent Development Table 42. JW Therapeutics Company Information Table 43. JW Therapeutics Business Overview Table 44. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 46. JW Therapeutics Recent Development Table 47. Johnson And Johnson Company Information Table 48. Johnson And Johnson Business Overview Table 49. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 51. Johnson And Johnson Recent Development Table 52. Novartis Company Information Table 53. Novartis Business Overview Table 54. Novartis CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 56. Novartis Recent Development Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 61. Roche Recent Development Table 62. CARsgen Therapeutics Company Information Table 63. CARsgen Therapeutics Business Overview Table 64. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 66. CARsgen Therapeutics Recent Development Table 67. Chongqing Precision Biotech Company Information Table 68. Chongqing Precision Biotech Business Overview Table 69. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 71. Chongqing Precision Biotech Recent Development Table 72. Gilead Sciences Company Information Table 73. Gilead Sciences Business Overview Table 74. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 76. Gilead Sciences Recent Development Table 77. HEBECELL Company Information Table 78. HEBECELL Business Overview Table 79. HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 81. HEBECELL Recent Development Table 82. Fosun Kite Bio Company Information Table 83. Fosun Kite Bio Business Overview Table 84. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 86. Fosun Kite Bio Recent Development Table 87. Legend Biotech Company Information Table 88. Legend Biotech Business Overview Table 89. Legend Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 91. Legend Biotech Recent Development Table 92. Beihai Biotechnology Company Information Table 93. Beihai Biotechnology Business Overview Table 94. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 96. Beihai Biotechnology Recent Development Table 97. AstraZeneca Company Information Table 98. AstraZeneca Business Overview Table 99. AstraZeneca CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 101. AstraZeneca Recent Development Table 102. Regeneron Pharmaceuticals Company Information Table 103. Regeneron Pharmaceuticals Business Overview Table 104. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 106. Regeneron Pharmaceuticals Recent Development Table 107. Kite Pharma Company Information Table 108. Kite Pharma Business Overview Table 109. Kite Pharma CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 111. Kite Pharma Recent Development Table 112. Celgene Company Information Table 113. Celgene Business Overview Table 114. Celgene CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 115. Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 116. Celgene Recent Development Table 117. Bristol Myers Squibb Company Information Table 118. Bristol Myers Squibb Business Overview Table 119. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 120. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 121. Bristol Myers Squibb Recent Development Table 122. Bluebird Bio Company Information Table 123. Bluebird Bio Business Overview Table 124. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026) Table 125. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio Table 126. Bluebird Bio Recent Development Table 127. North America CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026) & (US$ Million) Table 128. North America CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032) & (US$ Million) Table 129. North America CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026) & (US$ Million) Table 130. North America CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032) & (US$ Million) Table 131. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) Table 133. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032) Table 134. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026) & (US$ Million) Table 135. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032) & (US$ Million) Table 136. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026) & (US$ Million) Table 137. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032) & (US$ Million) Table 138. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) Table 140. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032) Table 141. China CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026) & (US$ Million) Table 142. China CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032) & (US$ Million) Table 143. China CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026) & (US$ Million) Table 144. China CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032) & (US$ Million) Table 145. Asia CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026) & (US$ Million) Table 146. Asia CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032) & (US$ Million) Table 147. Asia CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026) & (US$ Million) Table 148. Asia CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032) & (US$ Million) Table 149. Asia CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) Table 151. Asia CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032) Table 152. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026) & (US$ Million) Table 153. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032) & (US$ Million) Table 154. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026) & (US$ Million) Table 155. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032) & (US$ Million) Table 156. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026) Table 158. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. CAR-T Therapy For B-Cell Malignancies Product Image Figure 2. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global CAR-T Therapy For B-Cell Malignancies Market Share by Type: 2025 VS 2032 Figure 4. Universal CAR-T Image Figure 5. Dual Targets CAR-T Image Figure 6. Gene Modified Enhanced CAR-T Image Figure 7. Multi Targets CAR-T Image Figure 8. Single Target CAR-T Image Figure 9. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global CAR-T Therapy For B-Cell Malignancies Market Share by Application: 2025 VS 2032 Figure 11. Multiple Myeloma Image Figure 12. B-Cell Acute Lymphoblastic Leukemia Image Figure 13. B-Cell Non-Hodgkin's Lymphoma Image Figure 14. Others Image Figure 15. Global CAR-T Therapy For B-Cell Malignancies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 17. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global CAR-T Therapy For B-Cell Malignancies Market Share by Players in 2025 Figure 20. Global Top 5 and 10 CAR-T Therapy For B-Cell Malignancies Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2021-2032) Figure 24. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2021-2032) Figure 26. North America CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 27. North America CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032) Figure 28. North America CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032) Figure 29. North America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 30. United States CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 31. Canada CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 32. Mexico CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 33. Europe CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 34. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032) Figure 35. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032) Figure 36. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 37. Germany CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 38. France CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 39. U.K. CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 40. Italy CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 41. Russia CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 43. China CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 44. China CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032) Figure 45. China CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032) Figure 46. Asia CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 47. Asia CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032) Figure 48. Asia CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032) Figure 49. Asia CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 50. Japan CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 51. South Korea CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 54. India CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 55. Australia CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032) Figure 60. Brazil CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 61. South Africa CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 63. Turkey CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 64. Argentina CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 65. UAE CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 66. Egypt CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 67. Chile CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Universal CAR-T
  • Dual Targets CAR-T
  • Gene Modified Enhanced CAR-T
  • Multi Targets CAR-T
  • Single Target CAR-T
Applications
  • Multiple Myeloma
  • B-Cell Acute Lymphoblastic Leukemia
  • B-Cell Non-Hodgkin's Lymphoma
  • Others
Companies covered
  • IMCURE
  • JW Therapeutics
  • Johnson And Johnson
  • Novartis
  • Roche
  • CARsgen Therapeutics
  • Chongqing Precision Biotech
  • Gilead Sciences
  • HEBECELL
  • Fosun Kite Bio
  • Legend Biotech
  • Beihai Biotechnology
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Kite Pharma
  • Celgene
  • Bristol Myers Squibb
  • Bluebird Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Universal CAR-T
  5. 1.2.3 Dual Targets CAR-T
  6. 1.2.4 Gene Modified Enhanced CAR-T
  7. 1.2.5 Multi Targets CAR-T
  8. 1.2.6 Single Target CAR-T
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Multiple Myeloma
  12. 1.3.3 B-Cell Acute Lymphoblastic Leukemia
  13. 1.3.4 B-Cell Non-Hodgkin's Lymphoma
  14. 1.3.5 Others
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global CAR-T Therapy For B-Cell Malignancies Growth Trends by Region
  17. 1.5.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 CAR-T Therapy For B-Cell Malignancies Market Size by Region (2021-2026)
  19. 1.5.3 CAR-T Therapy For B-Cell Malignancies Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global CAR-T Therapy For B-Cell Malignancies Market Dynamics
  1. 2.1 CAR-T Therapy For B-Cell Malignancies Industry Trends
  2. 2.2 CAR-T Therapy For B-Cell Malignancies Industry Drivers
  3. 2.3 CAR-T Therapy For B-Cell Malignancies Industry Opportunities and Challenges
  4. 2.4 CAR-T Therapy For B-Cell Malignancies Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global CAR-T Therapy For B-Cell Malignancies Revenue by Company (2021-2026)
  2. 3.2 Global CAR-T Therapy For B-Cell Malignancies Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global CAR-T Therapy For B-Cell Malignancies Key Company Head office and Area Served
  4. 3.4 Global CAR-T Therapy For B-Cell Malignancies Company, Product Type & Application
  5. 3.5 Global CAR-T Therapy For B-Cell Malignancies Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global CAR-T Therapy For B-Cell Malignancies Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 CAR-T Therapy For B-Cell Malignancies Players Market Share by Revenue in 2025
  9. 3.6.3 2025 CAR-T Therapy For B-Cell Malignancies Tier 1, Tier 2, and Tier 3
4 CAR-T Therapy For B-Cell Malignancies Market by Type
  1. 4.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2032)
  3. 4.3 Global CAR-T Therapy For B-Cell Malignancies Market Size Share by Type (2021-2032)
5 CAR-T Therapy For B-Cell Malignancies Market by Application
  1. 5.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2032)
  3. 5.3 Global CAR-T Therapy For B-Cell Malignancies Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 IMCURE
  2. 6.1.1 IMCURE Company Information
  3. 6.1.2 IMCURE Business Overview
  4. 6.1.3 IMCURE CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 IMCURE CAR-T Therapy For B-Cell Malignancies Product Portfolio
  6. 6.1.5 IMCURE Recent Developments
  7. 6.2 JW Therapeutics
  8. 6.2.1 JW Therapeutics Company Information
  9. 6.2.2 JW Therapeutics Business Overview
  10. 6.2.3 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  12. 6.2.5 JW Therapeutics Recent Developments
  13. 6.3 Johnson And Johnson
  14. 6.3.1 Johnson And Johnson Company Information
  15. 6.3.2 Johnson And Johnson Business Overview
  16. 6.3.3 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product Portfolio
  18. 6.3.5 Johnson And Johnson Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Novartis CAR-T Therapy For B-Cell Malignancies Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Roche CAR-T Therapy For B-Cell Malignancies Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 CARsgen Therapeutics
  32. 6.6.1 CARsgen Therapeutics Company Information
  33. 6.6.2 CARsgen Therapeutics Business Overview
  34. 6.6.3 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product Portfolio
  36. 6.6.5 CARsgen Therapeutics Recent Developments
  37. 6.7 Chongqing Precision Biotech
  38. 6.7.1 Chongqing Precision Biotech Company Information
  39. 6.7.2 Chongqing Precision Biotech Business Overview
  40. 6.7.3 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  42. 6.7.5 Chongqing Precision Biotech Recent Developments
  43. 6.8 Gilead Sciences
  44. 6.8.1 Gilead Sciences Company Information
  45. 6.8.2 Gilead Sciences Business Overview
  46. 6.8.3 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product Portfolio
  48. 6.8.5 Gilead Sciences Recent Developments
  49. 6.9 HEBECELL
  50. 6.9.1 HEBECELL Company Information
  51. 6.9.2 HEBECELL Business Overview
  52. 6.9.3 HEBECELL CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 HEBECELL CAR-T Therapy For B-Cell Malignancies Product Portfolio
  54. 6.9.5 HEBECELL Recent Developments
  55. 6.10 Fosun Kite Bio
  56. 6.10.1 Fosun Kite Bio Company Information
  57. 6.10.2 Fosun Kite Bio Business Overview
  58. 6.10.3 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  60. 6.10.5 Fosun Kite Bio Recent Developments
  61. 6.11 Legend Biotech
  62. 6.11.1 Legend Biotech Company Information
  63. 6.11.2 Legend Biotech Business Overview
  64. 6.11.3 Legend Biotech CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Legend Biotech CAR-T Therapy For B-Cell Malignancies Product Portfolio
  66. 6.11.5 Legend Biotech Recent Developments
  67. 6.12 Beihai Biotechnology
  68. 6.12.1 Beihai Biotechnology Company Information
  69. 6.12.2 Beihai Biotechnology Business Overview
  70. 6.12.3 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product Portfolio
  72. 6.12.5 Beihai Biotechnology Recent Developments
  73. 6.13 AstraZeneca
  74. 6.13.1 AstraZeneca Company Information
  75. 6.13.2 AstraZeneca Business Overview
  76. 6.13.3 AstraZeneca CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 AstraZeneca CAR-T Therapy For B-Cell Malignancies Product Portfolio
  78. 6.13.5 AstraZeneca Recent Developments
  79. 6.14 Regeneron Pharmaceuticals
  80. 6.14.1 Regeneron Pharmaceuticals Company Information
  81. 6.14.2 Regeneron Pharmaceuticals Business Overview
  82. 6.14.3 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product Portfolio
  84. 6.14.5 Regeneron Pharmaceuticals Recent Developments
  85. 6.15 Kite Pharma
  86. 6.15.1 Kite Pharma Company Information
  87. 6.15.2 Kite Pharma Business Overview
  88. 6.15.3 Kite Pharma CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Kite Pharma CAR-T Therapy For B-Cell Malignancies Product Portfolio
  90. 6.15.5 Kite Pharma Recent Developments
  91. 6.16 Celgene
  92. 6.16.1 Celgene Company Information
  93. 6.16.2 Celgene Business Overview
  94. 6.16.3 Celgene CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Celgene CAR-T Therapy For B-Cell Malignancies Product Portfolio
  96. 6.16.5 Celgene Recent Developments
  97. 6.17 Bristol Myers Squibb
  98. 6.17.1 Bristol Myers Squibb Company Information
  99. 6.17.2 Bristol Myers Squibb Business Overview
  100. 6.17.3 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product Portfolio
  102. 6.17.5 Bristol Myers Squibb Recent Developments
  103. 6.18 Bluebird Bio
  104. 6.18.1 Bluebird Bio Company Information
  105. 6.18.2 Bluebird Bio Business Overview
  106. 6.18.3 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product Portfolio
  108. 6.18.5 Bluebird Bio Recent Developments
7 North America
  1. 7.1 North America CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
  2. 7.2 North America CAR-T Therapy For B-Cell Malignancies Market Size by Type
  3. 7.2.1 North America CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026)
  4. 7.2.2 North America CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032)
  5. 7.2.3 North America CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032)
  6. 7.3 North America CAR-T Therapy For B-Cell Malignancies Market Size by Application
  7. 7.3.1 North America CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026)
  8. 7.3.2 North America CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032)
  9. 7.3.3 North America CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032)
  10. 7.4 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country
  11. 7.4.1 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  13. 7.4.3 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
  14. 7.4.4 North America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
  2. 8.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Type
  3. 8.2.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026)
  4. 8.2.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032)
  5. 8.2.3 Europe CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032)
  6. 8.3 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Application
  7. 8.3.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026)
  8. 8.3.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032)
  9. 8.3.3 Europe CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032)
  10. 8.4 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country
  11. 8.4.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  13. 8.4.3 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
  14. 8.4.4 Europe CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
  2. 9.2 China CAR-T Therapy For B-Cell Malignancies Market Size by Type
  3. 9.2.1 China CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026)
  4. 9.2.2 China CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032)
  5. 9.2.3 China CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032)
  6. 9.3 China CAR-T Therapy For B-Cell Malignancies Market Size by Application
  7. 9.3.1 China CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026)
  8. 9.3.2 China CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032)
  9. 9.3.3 China CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
  2. 10.2 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Type
  3. 10.2.1 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026)
  4. 10.2.2 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032)
  5. 10.2.3 Asia CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032)
  6. 10.3 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Application
  7. 10.3.1 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026)
  8. 10.3.2 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032)
  9. 10.3.3 Asia CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032)
  10. 10.4 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Country
  11. 10.4.1 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  13. 10.4.3 Asia CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
  14. 10.4.4 Asia CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Type
  3. 11.2.1 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Application
  7. 11.3.1 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country
  11. 11.4.1 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst